Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cancer

Abemaciclib was newly approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high-risk early breast cancer (EBC). Clinical guidelines recommended abemaciclib as the first-line treatment for HR+/ HER2- EBC (early use) or HR+/ HER2- metastatic breast cancer (MBC) (delayed use).